Current and novel antibiotics against resistant Gram-positive bacteria

References

• [ATS] American Thoracic Society, Infectious Diseases Society of America2005Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumoniaAm J Respir Crit Care Med17138841615699079
   PubMed Web of Science ®Google Scholar
• AllenNELeTourneauDLHobbsJNJr1997Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residuesAntimicrob Agents Chemotherr416671
   PubMed Web of Science ®Google Scholar
• AllenNENicasTI2003Mechanism of action of oritavancin and related glycopeptide antibioticsFEMS Microbiol Rev265113212586393
   PubMed Web of Science ®Google Scholar
• AnthonyKBFishmanNOLinkinDR2008Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecyclineClin Infect Dis465677018199038
   PubMed Web of Science ®Google Scholar
• ArcherGLCoughterJPJohnstonJL1986Plasmid-encoded trimethoprim resistance in staphylococciAntimicrob Agents Chemother29733403729338
   PubMed Web of Science ®Google Scholar
• AriasCASinghKVPanessoD2007Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolatesAntimicrob Agents Chemother512043717438057
   PubMed Web of Science ®Google Scholar
• BabinchakTEllis-GrosseEDartoisN2005The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial dataClin Infect Dis41Suppl 5S35436716080073
   PubMed Web of Science ®Google Scholar
• BarberM1961Methicillin-resistant staphylococciJ Clin Pathol143859313686776
   PubMed Web of Science ®Google Scholar
• BhavnaniSMPassarellJAOwenJS2006Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremiaAntimicrob Agents Chemother50994100016495262
   PubMed Web of Science ®Google Scholar
• BilleterMZervosMJChenAY2008Dalbavancin: a novel once-weekly lipoglycopeptide antibioticClin Infect Dis465778318199045
   PubMed Web of Science ®Google Scholar
• BishopEMelvaniSHowdenBP2006Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patientsAntimicrob Agents Chemother50159960216569895
   PubMed Web of Science ®Google Scholar
• BogdanovichTEdnieLMShapiroS2005Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporinAntimicrob Agents Chemother4942101916189100
   PubMed Web of Science ®Google Scholar
• BoucherHWSakoulasG2007Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureusClin Infect Dis45601817682996
   PubMed Web of Science ®Google Scholar
• BoylanCJCampanaleKIversenPW2003Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionAntimicrob Agents Chemother471700612709343
   PubMed Web of Science ®Google Scholar
• BozdoganBEselDWhitenerC2003Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical CenterJ Antimicrob Chemother52864814563898
   PubMed Web of Science ®Google Scholar
• BrodieJJamiesonWSommervilleT1955Complications of oxytetracycline and tetracycline therapy related to a defined type of resistant staphylococcusLancet269223513243694
   PubMed Web of Science ®Google Scholar
• BushK2004Vancomycin-resistant Staphylococcus aureus in the clinic: not quite ArmageddonClin Infect Dis381056715095206
   PubMed Web of Science ®Google Scholar
• BushKHeepMMacielagMJ2007Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacyExpert Opin Investig Drug1641929
   PubMed Web of Science ®Google Scholar
• ChampneyWSRodgersWK2007Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cellsAntimicrob Agents Chemother513385717562806
   PubMed Web of Science ®Google Scholar
• ChangSSievertDMHagemanJC2003Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance geneN Engl J Med3481342712672861
   PubMed Web of Science ®Google Scholar
• CharlesPGWardPBJohnsonPD2004Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureusClin Infect Dis384485114727222
   PubMed Web of Science ®Google Scholar
• ClouseFLHovdeLBRotschaferJC2007In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysateAntimicrob Agents Chemother514521417908947
   PubMed Web of Science ®Google Scholar
• CourvalinP2006Vancomycin resistance in gram-positive cocciClin Infect Dis42Suppl 1S253416323116
   PubMed Web of Science ®Google Scholar
• CunhaBAMcDermottBNausheenS2007Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infectionJ Chemother (Florence, Italy)197534
   PubMed Web of Science ®Google Scholar
• DaviesTAPageMGShangW2007Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniaeAntimicrob Agents Chemother512621417470659
   PubMed Web of Science ®Google Scholar
• DavisonDBBarrettJF2003Antibiotics and pharmacogenomicsPharmacogenomics46576512943472
   PubMed Web of Science ®Google Scholar
• DeanCRVisalliMAProjanSJ2003Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Antimicrob Agents Chemother47972812604529
   PubMed Web of Science ®Google Scholar
• DemerecM1945Production of Staphylococcus strains resistant to various concentrations of penicillinProc Natl Acad Sci USA31162416588677
   PubMed Web of Science ®Google Scholar
• DeresinskiS2007Counterpoint: Vancomycin and Staphylococcus aureus – an antibiotic enters obsolescenceClin Infect Dis441543817516396
   PubMed Web of Science ®Google Scholar
• DeshpandeLMFritscheTRMoetGJ2007Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance programDiagn Microbiol Infect Dis581637017368801
   PubMed Web of Science ®Google Scholar
• Ellis-GrosseEJBabinchakTDartoisN2005The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonamClin Infect Dis41Suppl 5S3415316080072
   PubMed Web of Science ®Google Scholar
• FalagasMEMakrisGCDimopoulosG2008aHeteroresistance: a concern of increasing clinical significanceClin Microbiol Infect14101418093235
   PubMed Web of Science ®Google Scholar
• FalagasMESiemposIIVardakasKZ2008bLinezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trialsLancet Infect Dis8536618156089
   PubMed Web of Science ®Google Scholar
• FolenoBDAbbanatDGoldschmidtRM2007In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457Antimicrob Agents Chemother51361517101672
   PubMed Web of Science ®Google Scholar
• FowlerVGJrBoucherHWCoreyGR2006Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusN Engl J Med3556536516914701
   PubMed Web of Science ®Google Scholar
• GalesACSaderHSFritscheTR2008Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centersDiagn Microbiol Infect Dis60421718068934
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDWarrenYA2006In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infectionsAntimicrob Agents Chemother502875916870792
   PubMed Web of Science ®Google Scholar
• GotfriedMHShawJPBentonBM2008Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibioticsAntimicrob Agents Chemother5292717923490
   PubMed Web of Science ®Google Scholar
• HawserSLociuroSIslamK2006Dihydrofolate reductase inhibitors as antibacterial agentsBiochem Pharmacol71941816359642
   PubMed Web of Science ®Google Scholar
• HaydenMKRezaiKHayesRA2005Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureusJ Clin Microbiol435285716207998
   PubMed Web of Science ®Google Scholar
• HegdeSSReyesNSkinnerR2008Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureusJ Antimicrob Chemother611697217993505
   PubMed Web of Science ®Google Scholar
• HidayatLKHsuDIQuistR2006High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicityArch Intern Med16621384417060545
   PubMed Web of Science ®Google Scholar
• HigginsDLChangRDebabovDV2005Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother4911273415728913
   PubMed Web of Science ®Google Scholar
• HiramatsuKAritakaNHanakiH1997Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinLancet350167039400512
   PubMed Web of Science ®Google Scholar
• HobanDJBouchillonSKJohnsonBM2005In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)Diagn Microbiol Infect Dis522152716105567
   PubMed Web of Science ®Google Scholar
• HowdenBPWardPBCharlesPG2004Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibilityClin Infect Dis3852152814765345
   PubMed Web of Science ®Google Scholar
• JacobsMR2007Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and childrenFuture Microbiol259160018041900
   PubMed Web of Science ®Google Scholar
• JansenWTVerelAVerhoefJ2007In vitro activity of telavancin against gram-positive clinical isolates recently obtained in EuropeAntimicrob Agents Chemother513420417606689
   PubMed Web of Science ®Google Scholar
• JaureguiLEBabazadehSSeltzerE2005Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infectionsClin Infect Dis4114071516231250
   PubMed Web of Science ®Google Scholar
• JeffresMNIsakowWDohertyJA2006Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indicesChest1309475517035423
   PubMed Web of Science ®Google Scholar
• JonesME2007In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureusClin Microbiol Infect13Suppl 2172417488372
   PubMed Web of Science ®Google Scholar
• JonesRNFritscheTRSaderHS2005Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocolJ Chemother (Florence, Italy)17593600
   PubMed Web of Science ®Google Scholar
• JonesRNStilwellMGSaderHS2006Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)Diagn Microbiol Infect Dis541495316426793
   PubMed Web of Science ®Google Scholar
• KalilACPuumalaSStonerJ2006Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?Antimicrob Agents Chemother501910 author reply,19101116641477
   PubMed Web of Science ®Google Scholar
• KarlowskyJALaingNMBaudryT2007In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidisAntimicrob Agents Chemother511580117220418
   PubMed Web of Science ®Google Scholar
• KasiakouSKSermaidesGJMichalopoulosA2005Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trialsLancet infect Dis5581916122681
   PubMed Web of Science ®Google Scholar
• KazoryADibadjKWeinerID2006Rhabdomyolysis and acute renal failure in a patient treated with daptomycinJ Antimicrob Chemother57578916410267
   PubMed Web of Science ®Google Scholar
• KingAPhillipsIKanigaK2004Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJ Antimicrob Chemother5379780315028667
   PubMed Web of Science ®Google Scholar
• KingMDHumphreyBJWangYF2006Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infectionsAnn Intern Med1443091716520471
   PubMed Web of Science ®Google Scholar
• KohlhoffSASharmaR2007IclaprimExpert Opin Investig Drug1614418
   PubMed Web of Science ®Google Scholar
• KruegerWAKempfVAPeifferM2008Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coliJ Clin Microbiol468172018077630
   PubMed Web of Science ®Google Scholar
• Labandeira-ReyMCouzonFBoissetS2007Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumoniaScience (New York, N.Y)31511303
   PubMed Web of Science ®Google Scholar
• LalaniTBoucherHWCosgroveSE2008Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemiaJ Antimicrob Chemother6117718217999973
   PubMed Web of Science ®Google Scholar
• LaueHWeissLBernardiA2007In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of actionJ Antimicrob Chemother601391417962215
   PubMed Web of Science ®Google Scholar
• LeachKLSwaneySMColcaJR2007The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaMol Cell2639340217499045
   PubMed Web of Science ®Google Scholar
• LeuthnerKDCheungCMRybakMJ2006Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJ Antimicrob Chemother583384316787952
   PubMed Web of Science ®Google Scholar
• LinGCreditoKEdnieLM2005Antistaphylococcal activity of dalbavancin, an experimental glycopeptideAntimicrob Agents Chemother49770215673763
   PubMed Web of Science ®Google Scholar
• LivermoreDM2006Can beta-lactams be re-engineered to beat MRSA?Clin Microbiol Infect12Suppl 2111616524423
   PubMed Web of Science ®Google Scholar
• LivermoreDM2005Tigecycline: what is it, and where should it be usedJ Antimicrob Chemother566111416120626
   PubMed Web of Science ®Google Scholar
• LivermoreDMWarnerMMushtaqS2007In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococciAntimicrob Agents Chemother5111121417210773
   PubMed Web of Science ®Google Scholar
• LodiseTPJrPypstraRKahnJB2007Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsAntimicrob Agents Chemother5123788717387149
   PubMed Web of Science ®Google Scholar
• McAleeseFWuSWSieradzkiK2006Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycinJ Bacteriol18811203316428416
   PubMed Web of Science ®Google Scholar
• McKinnonPSSorensenSVLiuLZ2006Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infectionsAnn Pharmacother4010172316720705
   PubMed Web of Science ®Google Scholar
• MeagherAKAmbrosePGGraselaTH2005The pharmacokinetic and pharmacodynamic profile of tigecyclineClin Infect Dis41Suppl 5S33334016080071
   PubMed Web of Science ®Google Scholar
• MekaVGGoldHS2004Antimicrobial resistance to linezolidClin Infect Dis3910101515472854
   PubMed Web of Science ®Google Scholar
• MerouehSOBenczeKZHesekD2006Three-dimensional structure of the bacterial cell wall peptidoglycanProc Natl Acad Sci USA1034404916537437
   PubMed Web of Science ®Google Scholar
• MicekST2007Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infectionsClin Infect Dis45Suppl 3S18419017712745
   PubMed Web of Science ®Google Scholar
• MohrJFMurrayBE2007Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureusClin Infect Dis4415364217516395
   PubMed Web of Science ®Google Scholar
• Moise-BroderPAForrestABirminghamMC2004aPharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsClin Pharmacokinet439254215509186
   PubMed Web of Science ®Google Scholar
• Moise-BroderPASakoulasGEliopoulosGM2004bAccessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapyClin Infect Dis381700515227615
   PubMed Web of Science ®Google Scholar
• Munoz-PriceLSLolansKQuinnJP2006Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecyclineScand J Infect Dis381081417148081
   PubMed Web of Science ®Google Scholar
• MurrayBE1990The life and times of the EnterococcusClin Microbiol Rev346652404568
   PubMed Web of Science ®Google Scholar
• MurthyBSchmitt-HoffmannA2008Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activityClin Pharmacokinet47213318076216
   PubMed Web of Science ®Google Scholar
• MushtaqSWarnerMGeY2007In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypesJ Antimicrob Chemother603001117548456
   PubMed Web of Science ®Google Scholar
• MwangiMMWuSWZhouY2007Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencingProc Natl Acad Sci USA1049451617517606
   PubMed Web of Science ®Google Scholar
• Navon-VeneziaSLeavittACarmeliY2007High tigecycline resistance in multidrug-resistant Acinetobacter baumanniiJ Antimicrob Chemother59772417353223
   PubMed Web of Science ®Google Scholar
• NoelGJBushKBagchiP2008aA randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infectionsClin Infect Dis466475518225981
   PubMed Web of Science ®Google Scholar
• NoelGJStraussRSAmslerK2008bResults of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteriaAntimicrob Agents Chemother52374417954698
   PubMed Web of Science ®Google Scholar
• NovielloSIannielloFEspositoS2001In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococciJ Antimicrob Chemother48283611481302
   PubMed Web of Science ®Google Scholar
• OranjeAPChosidowOSacchidanandS2007Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority studyDermatology (Basel, Switzerland)21533140
   PubMed Web of Science ®Google Scholar
• PaceJLYangG2006Glycopeptides: Update on an old successful antibiotic classBiochem Pharmacol719688016412985
   PubMed Web of Science ®Google Scholar
• PageMG2006Anti-MRSA beta-lactams in developmentCurr Opin Pharmacol648048516899405
   PubMed Web of Science ®Google Scholar
• PatersonDL2006Clinical experience with recently approved antibioticsCurr Opin Pharmacol64869016904377
   PubMed Web of Science ®Google Scholar
• PillaiSKSakoulasGWennerstenC2002Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotypeJ Infect Dis1861603712447736
   PubMed Web of Science ®Google Scholar
• PillarCMAranzaMKShahD2008In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European originJ Antimicrob Chemother6159560218218646
   PubMed Web of Science ®Google Scholar
• QueenanAMShangWKaniaM2007Interactions of ceftobiprole with {beta}-lactamases from molecular classes A to DAntimicrob Agents Chemother5130899517591851
   PubMed Web of Science ®Google Scholar
• RoseWELeonardSNRossiKL2008Relationships between vancomycin pharmacodynamics and the emergence of vancomycin-intermediate Staphylococcus aureus (VISA) from heterogeneous VISA in an in vitro pharmacodynamic modelJ Antimicrob Chemotherdoi:10.1093/jac/dkn037.
   Web of Science ®Google Scholar
• RoseWERybakMJ2006Tigecycline: first of a new class of antimicrobial agentsPharmacotherapy26109911016863487
   PubMed Web of Science ®Google Scholar
• RoseWERybakMJKaatzGW2007aEvaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategiesJ Antimicrob Chemother603344017540670
   PubMed Web of Science ®Google Scholar
• RoseWERybakMJTsujiBT2007bCorrelation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and functionJ Antimicrob Chemother591190317434881
   PubMed Web of Science ®Google Scholar
• RossoliniGM2007Redesigning beta-lactams to combat resistance: summary and conclusionsClin Microbiol Infect13Suppl 230317488374
   PubMed Web of Science ®Google Scholar
• RovetaSMarcheseASchitoGC2008Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus sppInt J Antimicrob Agents31321818201873
   PubMed Web of Science ®Google Scholar
• RubinsteinECammarataSOliphantT2001Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter studyClin Infect Dis324021211170948
   PubMed Web of Science ®Google Scholar
• RuheJJMonsonTBradsherRW2005Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literatureClin Infect Dis4014293415844065
   PubMed Web of Science ®Google Scholar
• RybakMJ2006The pharmacokinetic and pharmacodynamic properties of vancomycinClin Infect Dis42Suppl 1S353916323118
   PubMed Web of Science ®Google Scholar
• SabathLDFinlandM1962Inactivation of methicillin, oxacillin and ancillin by Staphylococcus aureusProc Soc Exp Biol Med1115475013975861
   PubMed Web of Science ®Google Scholar
• SaderHSFritscheTRJonesRN2008aAntimicrobial activity of ceftaroline and ME1036 tested against clinical strains of community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA)Antimicrob Agents Chemotherdoi:10.1128/AAC.01351-07.
   Web of Science ®Google Scholar
• SaderHSFritscheTRKanigaK2005Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strainsAntimicrob Agents Chemother4935011216048970
   PubMed Web of Science ®Google Scholar
• SaderHSWattersAAFritscheTR2008bActivity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centersJ Chemother (Florence, Italy)202832
   Web of Science ®Google Scholar
• SaderHSWattersAAFritscheTR2007Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)BMC Infect Dis72917442104
   PubMed Web of Science ®Google Scholar
• SakoulasGEliopoulosGMFowlerGMJr2005Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) functionAntimicrob Agents Chemother4926879215980337
   PubMed Web of Science ®Google Scholar
• SakoulasGEliopoulosGMMoelleringRCJr2003Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistanceJ Infect Dis1879293812660939
   PubMed Web of Science ®Google Scholar
• SakoulasGMoelleringRCJrEliopoulosGM2006Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapyClin Infect Dis42Suppl 1S405016323119
   PubMed Web of Science ®Google Scholar
• SakoulasGMoise-BroderPASchentagJ2004Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremiaJ Clin Microbiol42239840215184410
   PubMed Web of Science ®Google Scholar
• SchneiderPHawserSIslamK2003Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteriaBioorgMed Chem Lett13421721
   PubMed Web of Science ®Google Scholar
• SchwaberMJWrightSBCarmeliY2003Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremiaEmerg Infect Dis96576412781004
   PubMed Web of Science ®Google Scholar
• SeltzerEDorrMBGoldsteinBP2003Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infectionsClin Infect Dis37129830314583862
   PubMed Web of Science ®Google Scholar
• ShawJPSeroogyJKanigaK2005Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjectsAntimicrob Agents Chemother4919520115616296
   PubMed Web of Science ®Google Scholar
• ShorrAFKunkelMJKollefM2005Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studiesJ Antimicrob Chemother569232916195255
   PubMed Web of Science ®Google Scholar
• SieradzkiKLeskiTDickJ2003Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapyJ Clin Microbiol4116879312682161
   PubMed Web of Science ®Google Scholar
• SieradzkiKRobertsRBHaberSW1999The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infectionN Engl J Med3405172310021472
   PubMed Web of Science ®Google Scholar
• SievertDMRudrikJTPatelJB2008Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006Clin Infect Dis466687418257700
   PubMed Web of Science ®Google Scholar
• SilvermanJAMortinLIVanpraaghAD2005Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impactJ Infect Dis19121495215898002
   PubMed Web of Science ®Google Scholar
• SimonGLSmithRHSandeMA1983Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two casesRev Infect Dis5Suppl 3S50786635441
   PubMedGoogle Scholar
• SmithTLPearsonMLWilcoxKR1999Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working GroupN Engl J Med34049350110021469
   PubMed Web of Science ®Google Scholar
• SorianoAMarcoFMartinezJA2008Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremiaClin Infect Dis4619320018171250
   PubMed Web of Science ®Google Scholar
• SteenbergenJNAlderJThorneGM2005Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infectionsJ Antimicrob Chemother55283815705644
   PubMed Web of Science ®Google Scholar
• SteinGESchooleySPeloquinCA2007Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infectionsJ Antimicrob Chemother608192317673476
   PubMed Web of Science ®Google Scholar
• StevensDLHerrDLampirisH2002Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infectionsClin Infect Dis3414819012015695
   PubMed Web of Science ®Google Scholar
• StevensDLMaYSalmiDB2007Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureusJ Infect Dis1952021117191165
   PubMed Web of Science ®Google Scholar
• StreitJMFritscheTRSaderHS2004Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolatesDiagn Microbiol Infect Dis481374314972384
   PubMed Web of Science ®Google Scholar
• StreitJMSaderHSFritscheTR2005Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogensDiagn Microbiol Infect Dis533071015922534
   PubMed Web of Science ®Google Scholar
• StryjewskiMEChuVHO’RiordanWD2006Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyAntimicrob Agents Chemother50862716495243
   PubMed Web of Science ®Google Scholar
• StryjewskiMEO’RiordanWDLauWK2005Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteriaClin Infect Dis401601715889357
   PubMed Web of Science ®Google Scholar
• SwensonJMTenoverFC2002In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureusJ Antimicrob Chemother498455012003982
   PubMed Web of Science ®Google Scholar
• TalbotGHBradleyJEdwardsJEJr2006Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClin Infect Dis426576816447111
   PubMed Web of Science ®Google Scholar
• TalbotGHThyeDDasA2007Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsAntimicrob Agents Chemother5136121617682094
   PubMed Web of Science ®Google Scholar
• TenoverFCMoelleringRCJr2007The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureusClin Infect Dis4412081517407040
   PubMed Web of Science ®Google Scholar
• VandeneschFNaimiTEnrightMC2003Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergenceEmerg Infect Dis99788412967497
   PubMed Web of Science ®Google Scholar
• VisalliMAMurphyEProjanSJ2003AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilisAntimicrob Agents Chemother47665912543675
   PubMed Web of Science ®Google Scholar
• VossAMoutonJWvan ElzakkerEP2007A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA)Ann Clin Microbiol Antimicrobiol69
   Google Scholar
• VoyichJMOttoMMathemaB2006Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus diseaseJ Infect Dis19417617017109350
   PubMed Web of Science ®Google Scholar
• WalshTRHoweRAWoottonM2001Detection of glycopeptide resistance in Staphylococcus aureusJ Antimicrob Chemother47357811222571
   PubMed Web of Science ®Google Scholar
• WeigeltJItaniKStevensDLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother492260615917519
   PubMed Web of Science ®Google Scholar
• WunderinkRGRelloJCammarataSK2003Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumoniaChest12417899714605050
   PubMed Web of Science ®Google Scholar
• WysockiMDelatourFFaurissonF2001Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized studyAntimicrob Agents Chemother452460711502515
   PubMed Web of Science ®Google Scholar
• YamaokaT2007The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSAJ Infect Chemother13141617593499
   PubMedGoogle Scholar
• YanKMaddenLChoudhryAE2006Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomesAntimicrob Agents Chemother5038758116940066
   PubMed Web of Science ®Google Scholar
• ZeckelMLPrestonDAAllenBS2000In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance studyAntimicrob Agents Chemother441370410770782
   PubMed Web of Science ®Google Scholar